Mouse model of primary biliary cirrhosis with progressive fibrosis: Are we there yet?

Hepatology

Volumn 57, Issue 2, 2013, Pages 429-431

  Popov, Yury ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 12P35; INTERLEUKIN 23; INTERLEUKIN 35; TRANSFORMING GROWTH FACTOR BETA2;

ANIMAL MODEL; AUTOIMMUNE DISEASE; CD8+ T LYMPHOCYTE; CYTOKINE RELEASE; DISEASE COURSE; DISEASE MODEL; EDITORIAL; FLUORESCENCE ACTIVATED CELL SORTING; GENE INACTIVATION; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; LIVER FIBROSIS; MONONUCLEAR CELL; NATURAL KILLER T CELL; NONHUMAN; PHENOTYPE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; TH1 CELL; TH17 CELL;

ANIMALS; INTERLEUKIN-12 SUBUNIT P35; LIVER CIRRHOSIS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA;

EID: 84873289639     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25969     Document Type: Editorial

References (22)

1. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005; 353: 1261-1273.
2. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ; American Association for Study of Liver Disease. Primary biliary cirrhosis. HEPATOLOGY 2009; 50: 291-308.
3. Gershwin ME, Mackay IR. The causes of primary biliary cirrhosis: convenient and inconvenient truths. HEPATOLOGY 2008; 47: 737-745.
4. Lee J, Belanger A, Doucette JT, Stanca C, Friedman S, Bach N. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007; 5: 1313-1315.
5. Concepcion AR, Medina JF. Approaches to the pathogenesis of primary biliary cirrhosis through animal models. Clin Res Hepatol Gastroenterol 2012; 36: 21-28.
6. Tsuda M, Zhang W, Yang GX, Tsuneyama K, Ando Y, Kawata K, et al. Deletion of IL-12p35 induces liver fibrosis in dominant negative transforming growth factor beta receptor type II mice. HEPATOLOGY 2013; 57: 806-816.
7. Gorelik L, Flavell RA. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 2000; 12: 171-181.
8. Oertelt S, Lian ZX, Cheng CM, Chuang YH, Padgett KA, He XS, et al. Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J Immunol 2006; 177: 1655-1660.
9. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007; 450: 566-569.
10. Yoshida K, Yang GX, Zhang W, Tsuda M, Tsuneyama K, Moritoki Y, et al. Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type II mice. HEPATOLOGY 2009; 50: 1494-1500.
11. Hirschfield GM, Liu X, Xu C, Lu Y, Xie G, Lu Y, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 2009; 360: 2544-2555.
12. Diveu C, McGeachy MJ, Cua DJ. Cytokines that regulate autoimmunity. Curr Opin Immunol 2008; 20: 663-668.
13. Hammerich L, Heymann F, Tacke F. Role of IL-17 and Th17 cells in liver diseases. Clin Dev Immunol 2011; 2011: 345803.
14. Wu SJ, Yang YH, Tsuneyama K, Leung PS, Illarionov P, Gershwin ME, et al. Innate immunity and primary biliary cirrhosis: activated invariant natural killer T cells exacerbate murine autoimmune cholangitis and fibrosis. HEPATOLOGY 2011; 53: 915-925.
15. Mattner J, Savage PB, Leung P, Oertelt SS, Wang V, Trivedi O, et al. Liver autoimmunity triggered by microbial activation of natural killer T cells. Cell Host Microbe 2008; 3: 304-315.
16. Popov Y, Schuppan D. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. HEPATOLOGY 2009; 50: 1294-1306.
17. Bissell DM. Therapy for hepatic fibrosis: revisiting the preclinical models. Clin Res Hepatol Gastroenterol 2011; 35: 521-525.
18. Hillebrandt S, Goos C, Matern S, Lammert F. Genome-wide analysis of hepatic fibrosis in inbred mice identifies the susceptibility locus Hfib1 on chromosome 15. Gastroenterology 2002; 123: 2041-2051.
19. Popov Y, Sverdlov DY, Sharma AK, Bhaskar KR, Li S, Freitag TL, et al. Tissue transglutaminase does not affect fibrotic matrix stability or regression of liver fibrosis in mice. Gastroenterology 2011; 140: 1642-1652.
20. Fickert P, Stoger U, Fuchsbichler A, Moustafa T, Marschall HU, Weiglein AH, et al. A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis. Am J Pathol 2007; 171: 525-536.
21. Popov Y, Patsenker E, Fickert P, Trauner M, Schuppan D. Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol 2005; 43: 1045-1054.
22. Garrido MC, Hubscher SG. Accuracy of staging in primary biliary cirrhosis. J Clin Pathol 1996; 49: 556-559.